Well Health Stock: Could This Healthcare Champion Hit New Highs in 2025?

Down over 30% from all-time highs, Well Health is a TSX stock that trades at a reasonable multiple in 2025.

| More on:
doctor uses telehealth

Source: Getty Images

Valued at a market cap of $1.68 billion, Well Health (TSX:WELL) went public in 2016. Since its initial public offering (IPO), WELL stock has returned 6,630% to shareholders. So, an investment of $500 in the TSX stock soon after its IPO would be worth close to $33,500 today. Despite these market-thumping gains, Well Health stock trades 27% below all-time highs, allowing you to buy a quality company at a lower multiple. Let’s see if the Canadian telehealth stock is a good buy in 2025.

Can WELL stock rebound in 2025?

Well Health operates a Practitioner Enablement Platform with two revenue models:

  • Fully managed services for physicians at WELL-owned clinics
  • Ala carte solutions for independent practitioners

In Canada, WELL is the largest operator of outpatient clinics with 181 locations across four provinces, offering healthcare services. The U.S. division comprises CRH (gastrointestinal care and practitioner recruiting), Circle Medical (primary care/mental health), and Wisp (women’s telehealth). The technology segment includes WELL Provider Solutions (EMR systems, billing services, digital health marketplace) and WELL Cybersecurity.

Over the years, the company has grown through strategic acquisitions. Its sales have risen from 5.9 million in 2018 to $776.1 million in 2023. In the last 12 months, revenue has grown by 36.6% year over year to $957.7 million.

Well’s business model aims to address challenges in Canadian healthcare, a $344 billion industry struggling with fragmentation, underinvestment, and technological limitations.

A strong performance in Q3 of 2024

WELL Health reported solid numbers in the third quarter (Q3) of 2024, with sales of $251.7 million, up 23% year over year. The Canadian Patient Services segment rose by 35%, while U.S. Patient Services and SaaS Technology Services grew by 21% and 19%, respectively, in the September quarter. Notably, Well Health surpassed $1 billion in annualized run rate ahead of schedule while patient visits grew by 41% to 1.5 million.

Well Health’s strategic initiatives include a pipeline of 17 pending acquisitions worth over $100 million in revenues. Moreover, the company has expanded its service offerings by launching weight care and GLP-1 programs in Canada and the U.S.

Well’s U.S.-based platforms, Wisp and Circle Medical, showcased robust performance in Q3 with 35% and 61% revenue growth, respectively, and are currently under strategic review for a potential sale.

What is the target price for Well Health stock?

Well Health’s management plans to continue its share buyback program while reducing debt and minimizing share dilutions. Further, it aims to maintain a strong financial position, enabling continued funding of organic growth and future acquisitions through operational cash flows.

Looking ahead, WELL has raised its 2024 revenue guidance to $985-995 million and remains focused on enhancing profitability. It implemented a cost-cutting program that contributed to record adjusted earnings before interest, tax, depreciation, and amortization of $32.7 million in Q3 of 2024. It also generated $16.2 million in free cash flow in Q3.

Analysts tracking Well Health forecast it will grow sales from $776 million in 2023 to $1.11 billion in 2025. Further, free cash flow is estimated at $83 million in 2025, up from $58.33 million in 2023. So, priced at 20.2 times forward FCF, Well Health stock is not too expensive and trades at a 25% discount, given consensus price targets.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Tech Stocks

data analyze research
Tech Stocks

2 Under-$5 Hidden Gems Worth Your Attention

Investors need to understand that plenty of penny stocks might be safer compared to several large-cap investors.

Read more »

Skiier goes down the mountain on a sunny day
Tech Stocks

Meet the Canadian Stock That Continues to Crush the Market 

It's normal to beat the market once or twice while riding a trend. But this stock has been crushing the…

Read more »

Hourglass and stock price chart
Tech Stocks

2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Growth stocks are amazing, but only when they have a true growth outlook. Luckily, these two match right up.

Read more »

Tech Stocks

Why I’m Bearish on Celestica Stock, and What I’m Buying Instead

Celestica stock has exploded in share price, but the future doesn't look as certain. So why not consider this stock…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Investing in Canadian AI Stocks for Maximum Gains in 2025

Artificial intelligence stocks look strong for the future, but Kinaxis stock could be the best buy out there.

Read more »

how to save money
Tech Stocks

Best Canadian Stocks to Buy With $7,000 Right Now

Some of the best stocks to buy today are tech stocks like Blackberry, due to their potential for growth in…

Read more »

space ship model takes off
Dividend Stocks

TSX on the Rise: 2 Momentum Stocks to Buy Immediately 

The TSX Composite Index started marching upwards in mid-January. Among the stocks that rallied, a few are picking up momentum.

Read more »

Technology
Tech Stocks

Shopify: Buy, Sell, or Hold in 2025?

Shopify stock has long been known for giving investors a wild ride. But could that be over in 2025?

Read more »